PLAU and neoplasm: We assessed 4146 node-negative breast cancer patients by clinico-pathological or tumor-biological prognostic factors (uPA/PAI-1), and 2541 of these were classified as high-risk and, therefore, treated with six courses of a standard anthracycline combination (FEC) or, by randomization, three courses of the same combination followed by three courses of docetaxel.